We’re advancing a pipeline of novel broad-spectrum antivirals

Kimer Med is developing a pipeline of novel, broad-spectrum antiviral drug candidates. With success against 21 different viruses so far, we’re taking on the global health challenge of viral disease and future pandemic threats.

OUR SCIENCE

THE PROBLEM

Viruses infect billions, kill millions and cost trillions

Viruses wreak havoc on global health, causing enormous human suffering and devastating economic consequences.

Right now, 95% of viruses that infect humans lack an approved antiviral treatment.
With so many unmet medical needs and the constant risk of new viruses emerging, the global community is currently under-equipped to confront these evolving threats.

LEARN MORE

THE SOLUTION

Kimer Med scientist holding a beaker of solution

Our proprietary platform that enables the rapid design and optimisation of broad-spectrum antiviral drug candidates.

Learn more

Our progress so far

Kimer Med scientist testing broad-spectrum antiviral drugs

Results against 21 viruses

Multiple in vitro studies confirm our platform's broad-spectrum capability, with efficacy against 21 different viruses across 9 virus families.

$14 million Series A raise

Our successful Series A round closed in October 2024 with NZD$14 million raised. This funding will carry us through the next few years as we progress towards Phase 1 trials.

LEARN MORE

A rack of vials containing antiviral proteins Kimer Med

Positive early in vivo data

Early-stage in vivo data confirms the efficacy and low toxicity of our antiviral compounds. More studies are currently underway.

Small pharma, big plans

We're a small team in a small county, but we’re taking on some of the world's biggest health challenges.

Our people

Governments

Now is the time to invest in pandemic preparedness to protect populations. Talk to us about our pipeline of broad-spectrum antiviral candidates.

Defence Agencies

Deploy our proven broad-spectrum antiviral platform against any viral threat. Sponsor the development of MCMs to counter operational threats and enhance force protection.

Philanthropic Organisations

Support our vital work and make a huge positive impact in the world by reducing suffering and disease.

Pharmaceutical companies

We’re looking to partner with other pharmaceutical companies to license our antiviral candidates and bring them to market faster.

Horizon Europe

We are actively seeking partners for Horizon Europe funding calls, particularly in Pillar 2 Health (focused on pandemic preparedness, infectious diseases). Please get in touch.

Partner with us to advance antiviral solutions

Antiviral Researchers

Parallel research streams using our pipeline of novel broad-spectrum antiviral candidates can help get vital therapeutics to patients in need in less time.

CONTACT US

Development Agencies

Developing counties bear the brunt of infectious viral diseases. If you fund or carry out research into neglected viral diseases, we can speed things up by working together.

Why the world needs Broad-Spectrum Antivirals (BSAs)

Viral diseases

Viruses infect billions, kill millions and cost trillions
The majority of viral diseases have no approved treatment or vaccine
The next pandemic could be caused by a currently unknown virus (Virus X)
Biowarfare or bioterror events could involve multiple unknown viruses

Vaccines have limitations

Vaccine effectiveness varies widely across different viruses
Vaccines won’t be ready when the next pandemic occurs
Viruses can evolve quickly, rendering vaccines less effective
Some people can’t or won’t take vaccines

Broad-spectrum antivirals

BSAs can be used to treat a wide range of existing viral diseases
BSAs can be given as soon as an outbreak is identified
BSAs can provide vital protection for frontline health workers and first responders
BSAs can be used to prevent the spread of disease, reducing outbreak severity

Awards & Recognition